We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Roberto Pili

Roberto Pili MD

Robert Wallace Miller Professor of Oncology, Director, Genitourinary Oncology, Professor of Medicine, Urology, Pharmacology and Toxicology, Indiana University, School of Medicine – Simon Cancer Center, Indianapolis, IN

Roberto Pili, MD, is the Director of Genitourinary Oncology, co-Leader of the Experimental and Developmental Therapeutics Program at the Indiana University Melvin and Bren Simon Cancer Center and co-Leader of the Indiana Genitourinary Malignancies Research Consortium. He is also the Robert Wallace Miller Professor of Oncology at the Indiana University School of Medicine.  Dr. Pili has received his medical degree from the Catholic University in Rome, his internal medicine training from Albert Einstein-Montefiore Medical Center, and has completed a fellowship in medical oncology at the Johns Hopkins University.

Dr. Pili is a translational researcher and a nationally recognized expert in prostate, renal and bladder cancers. His research focuses on the development of novel therapeutic agents, including epigenetic agents such as histone deacetylase inhibitors, and understanding their immunomodulatory effects.  He also conducts phase I/II clinical trials of novel agents for the treatment of genitourinary malignancies.  Dr. Pili is the recipient of research grants from the National Cancer Institute, and is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.  He serves as a reviewer for study sections of the NCI and the Department of Defense, and he has authored or co-authored more than 190 journal publications and book chapters.

Disclosures

Dr. Roberto Pili receives research support from Bristol-Meyer Squibb, Genentech, Syndax, Clinigen, Epizyme, and Merck.